Abbott to Spin Off $8.5B Nutrition Unit, Sharpening Focus on Medtech and Diagnostics

What happened

Abbott announced plans to separate its nutrition business into a standalone company with about $8.5 billion in annual revenue, a move that removes a struggling segment from the core portfolio. The nutrition unit has been a persistent drag, with first-half 2026 sales down 5.6% ex-FX and Q2 volumes down 3.6%, reflecting weak demand and pricing actions. This decision follows Abbott's $20.6 billion Exact Sciences acquisition, which expanded debt and shifted focus toward medtech and cancer diagnostics. By carving out nutrition, Abbott aims to sharpen its growth profile and potentially improve margins, but the separation also forfeits a stable, albeit low-growth, cash generator and diversification buffer. The market will need clarity on spin-off structure, tax treatment, and whether investors receive shares or Abbott monetizes the asset, as well as how the remaining company will absorb the loss of nutrition's ~$8.5B revenue and operating cash flow.

Implication

Investors should view the separation as an attempt to reset the narrative toward higher-growth medtech and diagnostics, but the benefits are not guaranteed until the transaction details are clear. A spin-off to shareholders would avoid a taxable sale and keep Abbott shareholders exposed to any value creation, but it would also leave Abbott more concentrated in cyclical procedure-driven markets. If Abbott instead sells the nutrition business, it could raise cash to pay down debt from the Exact acquisition, but likely at a discount given nutrition's declining volumes. The remaining company would need to maintain overall revenue growth and margin expansion to justify its current 34.5x earnings multiple, which may become harder without nutrition's contribution. Near-term, the stock could re-rate on the strategic simplification, but investors should monitor the spin-off execution, any stranded costs, and the impact on Abbott's dividend capacity.

Thesis delta

The carve-out does not change the underlying thesis of waiting for better entry, but it removes one of the three key proof points (nutrition stabilization) from the near-term checklist. The bear case around nutrition dragging results is diminished, but the bear case around device growth and Exact dilution remains. The master report's WAIT rating and entry/targets may need upward adjustment if the market rewards the move, but until transaction details are known, we maintain a cautious stance.